Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

n US dollars. All currency figures reported in this document, including comparative figures, are reported in US dollars, unless otherwise specified.

For the three-month period ended December 31, 2007, the net loss amounted to $16,097,000 ($0.33 per share), compared to $17,011,000 ($0.44 per share) for the corresponding period in the previous year. For the year ended December 31, 2007, the net loss amounted to $81,486,000 ($1.85 per share), compared to $66,469,000 ($1.72 per share) for the same period the previous year.

The net loss for the year ended December 31, 2007, includes a non-recurring charge in the second quarter of fiscal 2007 under Canadian GAAP of $10,430,000 relating to the $40 million 5% senior subordinated convertible notes, which were fully converted into common shares during the second quarter of 2007. In total, accretion expense amounted to $15,751,000 for the year ended December 31, 2007.

Revenue from collaboration agreement amounted to $206,000 for the current quarter ($1,119,000 for the year), compared to $497,000 for the same period in the previous year ($2,106,000 for the year). This revenue is earned under the agreement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product candidate for the treatment of Amyloid A (AA) amyloidosis. Revenue recognized is in respect of the non-refundable upfront payment received from Centocor, which is being amortized over the estimated period through to the anticipated regulatory approval date of the investigational product candidate. The estimated period is subject to change based on additional information that the Company may receive periodically. The other portion of the upfront payment received from Centocor ($6,000,000) has been classified as deferred revenue and is not being amortized as earned revenue given that it is potentially refundable. In the event that the Company receives an approval letter issued by the US Food and Drug Adminis
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Durham, NC (PRWEB) , ... September 03, 2015 ... ... , August 31, 2015: DiabetesSisters is pleased to announce the additional of Carol ... August 2015 by current board members Diana Karczmarczyk, Donna Rice, David Warren, Matt ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the complete faculty ... September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry experts ...
(Date:9/3/2015)... OR (PRWEB) , ... September 03, 2015 , ... ... finest responsibility concierges; simplifying responsibilities which can impact the delicate life balance between ... socio-economic situation might be.” - Jeffrey R. Leaptrott, CEO , A LifeMinder Plus® ...
(Date:9/3/2015)... ... September 03, 2015 , ... AvePoint, the established leader ... Service Pack (SP) 4 – AvePoint’s solution for facilitating two-way collaboration and external ... 2015 Trend-Setting Product”. This is the fifth consecutive year an AvePoint product has ...
(Date:9/3/2015)... ... 2015 , ... Mum n Me is pleased to announce the launch of ... that gives maximum protection from sun exposure, wind, bugs, and germs. The Mum n ... assurance by keeping the cover securely in place. The new car seat cover is ...
Breaking Medicine News(10 mins):Health News:Carol H. Wysham, MD, Joins DiabetesSisters Board of Directors 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Mum n Me Announces New Baby Car Seat Cover 2
... with severe problems in injection sites get benefited from ... of insulin) //– said The National Institute for Health ... suggestion has already said by the National Institute for ... not money worthy. ,But now the ...
... diabetics battle their illness with daily doses of ... diabetes, transplants of the pancreatic tissue// could help ... like blindness, amputation, kidney failure, and heart disease. ... organ donors available for transplantation. Insulin-producing pancreas tissues ...
... All India Institute of Medical Sciences (AIIMS) are helping the ... involving Rahul Mahajan. // ,The police have obtained ... Party (BJP) leader Pramod Mahajan, and managed to substantiate the ... the case, a senior official said. ,"Senior doctors ...
... medical company Biacore to complement its own healthcare division ... ,The Fairfield, Connecticut-based GE will purchase Biacore, which ... Swedish kroner ($438 million). , ,Pharmaceutical company ... Uppsala, Sweden-based Biacore, supports the bid, according to GE. ...
... wave therapy would cure ailments caused by irregular heartbeats, ... Electrophysiology said here today. // ,Speaking on ... Lifeline Hospital of the Dr K M Cherian Heart ... by irregular heartbeats, was prevalent among 10 per cent ...
... has revealed that the place of birth determines the life expectancy ... expectancy than those born in south east England //. ... to be 69.3 it was found to be 77 in East ... and it has ranked the 10 best and worst areas to ...
Cached Medicine News:Health News:Transplanted Pancreatic Tissue Could Help Diabetics 2Health News:AIIMS Doctors Assists Police in Rahul Mahajan’s Drug Abuse Cas 2Health News:Life Expectancy Determined by Place of Birth 2
(Date:9/3/2015)... and REHOVOT, Israel, Sept. 3, 2015 OticPharma, ... developing innovative therapies for ear, nose, and throat (ENT) ... Newport Gateway office complex to be the location of ... move by end of September and will have office ... Headquarters: OticPharma, Inc. 19900 MacArthur Blvd., Suite ...
(Date:9/2/2015)... YORK , Sept. 2, 2015  The report ... future market of breast cancer drugs on the basis ... cancer usually originates from the inner lining of milk ... is a malignant type of tumor that can spread ... of cancer which starts in lobules is referred as ...
(Date:9/2/2015)... Sept. 2, 2015 Advanced Wound Dressings ... Advanced dressings have steadily replaced traditional bandages ... variety of wound indications, such as trauma wounds, ... control, and physical protection become increasingly critical in ... in standard therapy. This report focuses on ...
Breaking Medicine Technology:OticPharma Establishes U.S. Headquarters in Orange County, California 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2
... The combination of these recommendations with the ... Sorin Group has resulted in numerous improvements, ... poles and reservoir holder for hassle-free storage ... cart with just a flick of the ...
The S4 Spinal System has quickly gained a reputation for being the next generation in pedicle screw systems because of its exceptionally small size and high biomechanical strength....
... Diagnostics is a clinical reference ... treatment and monitoring of hemostatic ... a collaboration of four laboratory ... defined vision to deliver customizable ...
All-natural porcine collagen can be used in open or laparoscopic placement....
Medicine Products: